Trials / Completed
CompletedNCT05610189
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Cerevel Therapeutics, LLC · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tavapadon | Oral tablets |
Timeline
- Start date
- 2022-12-15
- Primary completion
- 2023-12-12
- Completion
- 2023-12-17
- First posted
- 2022-11-09
- Last updated
- 2024-02-08
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05610189. Inclusion in this directory is not an endorsement.